Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087477 · ClinicalTrials.gov registry record · Phase 1
A Pilot Study of Pivanex in Patients With Malignant Melanoma
A Phase 1 study, sponsored by Titan Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00087477: Clinical Trial Phase 1 study, sponsored by Titan Pharmaceuticals.
NCT00087477 is a Phase 1 study that was terminated before completion, run by Titan Pharmaceuticals. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00087477, a Phase 1 study, was terminated before completion, sponsored by Titan Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This pilot study will assess the safety and efficacy of Pivanex alone in patients with malignant melanoma who have relapsed after treatment with chemotherapy or Interleukin-2 (IL-2). Pivanex is an investigational agent.
Interventions
- DRUG Pivanex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2004-01 |
| Est. Completion | 2004-08 |
| Phase | Phase 1 |
Why NCT00087477 stopped before completion
NCT00087477 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which Pivanex is the first listed.
NCT00087477 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00087477 about?
NCT00087477 is a clinical study titled "A Pilot Study of Pivanex in Patients With Malignant Melanoma". This pilot study will assess the safety and efficacy of Pivanex alone in patients with malignant melanoma who have relapsed after treatment with chemotherapy or Interleukin-2 (IL-2). Pivanex is an investigational agent.
What is the current status of trial NCT00087477?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2004-01. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00087477?
The interventions under investigation include: Pivanex (DRUG).
Who is sponsoring clinical trial NCT00087477?
This trial is sponsored by Titan Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00087477's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia